1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Chronic Disease Analysis & Statistics 2021 - Europe (p2)

Chronic Disease Analysis & Statistics 2021 - Europe (p2)

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Pharma Intelligence
31-46 of 36 reports

Cimzia

  • $ 10000
  • July 2018
  • 65 pages

Drug Overview Cimzia (certolizumab; UCB/Astellas [also marketed by Dermira in some approved indications]) is a PEGylated humanized monoclonal antibody fragment, with high affinity for both soluble and ...

  • United States
  • European Union
  • Monoclonal Antibody
  • Autoimmune Disease
  • Industry analysis

Nucala

  • $ 10000
  • July 2018
  • 27 pages

Drug Overview Nucala (mepolizumab; GlaxoSmithKline) is a humanized monoclonal immunoglobulin G1 antibody that binds to interleukin (IL)-5, which plays a significant role in the activation, proliferation, ...

  • Japan
  • United States
  • Asthma
  • Monoclonal Antibody
  • Industry analysis

Stiolto Respimat

  • $ 10000
  • July 2018
  • 21 pages

Drug Overview Stiolto Respimat ([olodaterol + tiotropium]; Boehringer Ingelheim) is a fixed-dose combination of the long-acting beta 2 agonist (LABA) olodaterol and the gold-standard long-acting muscarinic ...

  • United States
  • European Union
  • Respiratory Treatment
  • Healthcare
  • Industry analysis

Seebri Neohaler

  • $ 10000
  • July 2018
  • 17 pages

Drug Overview Novartis, under license from Vectura and Sosei, developed Seebri Neohaler, a once-daily inhaled formulation of glycopyrrolate. The once-daily long-acting muscarinic antagonist (LAMA) received ...

  • United States
  • Japan
  • Respiratory Disease
  • Healthcare
  • Industry analysis

Striverdi Respimat

  • $ 10000
  • July 2018
  • 16 pages

Drug Overview Striverdi (olodaterol; Boehringer Ingelheim) is a long-acting beta 2 agonist delivered via the Respimat inhaler. It is indicated for the once-daily maintenance treatment of airflow obstruction ...

  • Japan
  • United States
  • Respiratory Disease
  • Hospital
  • Industry analysis

Symbicort

  • $ 10000
  • July 2018
  • 30 pages

Drug Overview AstraZeneca’s Symbicort ([budesonide + formoterol]) was the second inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA) drug combination to launch on the respiratory market, starting ...

  • Japan
  • United States
  • Pharmaceutical
  • Respiratory Treatment
  • Industry analysis

Tudorza Pressair

  • $ 10000
  • July 2018
  • 17 pages

Drug Overview Tudorza Pressair (aclidinium; AstraZeneca/Circassia/Kyorin Pharmaceutical) is a twice-daily long-acting muscarinic antagonist indicated for the maintenance treatment of chronic obstructive ...

  • Europe
  • Japan
  • Respiratory Disease
  • Industry analysis

Trimbow

  • $ 10000
  • July 2018
  • 17 pages

Drug Overview Trimbow ([beclomethasone + formoterol + glycopyrrolate]; Chiesi Farmaceutici) is a fixed triple-combination product consisting of glycopyrrolate (a LAMA), formoterol (a LABA), and beclometasone ...

  • Europe
  • Generic Drug
  • Respiratory Disease
  • Industry analysis

Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026

  • $ 22000
  • April 2021
  • 64 pages

Disease Overview Chronic obstructive pulmonary disease (COPD) is defined by persistent airflow limitation (reduction in the ability to exhale at a normal rate and volume). While chronic and progressive ...

  • United States
  • World
  • Respiratory Disease
  • Industry analysis
  • Smoking Prevalence

Disease Analysis: Asthma

  • $ 22000
  • February 2021
  • 83 pages

Defintion Asthma is a chronic respiratory condition characterized by recurrent wheezing, coughing, and breathlessness, which occur in acute events known as exacerbations. Often triggered by factors such ...

  • World
  • Europe
  • Asthma
  • Industry analysis
  • Drug Approval
  • Asthma Prevalence

Disease Analysis: Asthma - Forecast and Market Analysis

  • $ 22000
  • December 2020
  • 81 pages

Defintion Asthma is a chronic respiratory condition characterized by recurrent wheezing, coughing, and breathlessness, which occur in acute events known as exacerbations. Often triggered by factors such ...

  • World
  • Europe
  • Asthma
  • Industry analysis
  • Asthma Prevalence
  • Drug Approval

Disease Analysis: Asthma - Forecast and Market Analysis to 2027

  • $ 22000
  • April 2020
  • 80 pages

Latest key takeaways The analyst estimates that in 2018, there were approximately 343.6 million prevalent cases of asthma in individuals aged up to 44 years worldwide, and forecasts that number to increase ...

  • World
  • Europe
  • Asthma
  • Industry analysis
  • Drug Approval
  • Asthma Prevalence

Diabetic Nephropathy Market and Forecast Analysis to 2026

  • $ 22000
  • February 2019
  • 236 pages

DISEASE OVERVIEW Diabetic nephropathy, also known as diabetic kidney disease, is caused by damage to small blood vessels which can cause the kidneys to be less efficient in their blood filtration role ...

  • Japan
  • United States
  • Renal Disease
  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Industry analysis

Ischemic Stroke Market and Forecast Analysis 2024

  • $ 22000
  • January 2019
  • 163 pages

Disease Overview Stroke is the second most common cause of death and a major cause of disability worldwide. A stroke occurs when there is a blockage or bleed in the cerebrovascular system that leads to ...

  • World
  • Japan
  • Stroke
  • Industry analysis

Rheumatoid Arthritis Market and Forecast Analysis to 2025

  • $ 22000
  • August 2018
  • 610 pages

DISEASE OVERVIEW Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to progressive joint deformity, disability, and occasionally premature death. RA may affect many tissues and organs, ...

  • Japan
  • United States
  • Arthritis
  • Environmental Services
  • Industry analysis
  • Mortality Rate

Anemia in Chronic Kidney Disease Market and Forecast Analysis to 2035, Pharma Intelligence

  • $ 22000
  • July 2018
  • 318 pages

Disease Overview Chronic kidney disease (CKD) is characterized by decreased kidney function and kidney damage. Damaged renal tissue has a diminished ability to produce erythropoietin, a hormone that stimulates ...

  • Japan
  • United States
  • Blood Disease
  • Chronic Disease
  • Industry analysis
About 5900 reports

Download Unlimited Documents from Trusted Public Sources

View report >

Respiratory Disease Demographic Impact in Wales (UK)

  • October 2021
  • 9 pages
  • Wales
  • Influenza
  • Respiratory Disease
  • Industry analysis
  • Vaccination Coverage
  • Influenza Prevalence

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on